- Aramis Biotechnologies and Biodextris Inc. have signed a strategic partnership to support the downstream manufacturing of clinical materials for Aramis’ seasonal influenza vaccine candidate.
- The collaboration will ensure timely production of high-quality materials for Aramis’ upcoming Phase 1 and 2 clinical trials, leveraging Biodextris’ advanced manufacturing capabilities.
Aramis Biotechnologies and Biodextris Inc. have formed a strategic partnership to advance the production of a seasonal influenza vaccine, focusing on supporting clinical trials and addressing the need for better protection of at-risk populations. The agreement will see Biodextris, a Montreal-based CDMO with expertise in cGMP biologics, provide Aramis with the necessary infrastructure and capabilities to manufacture clinical materials.
Under this agreement, Biodextris will assist with the downstream manufacturing of clinical materials for Aramis’ vaccine candidate, which is slated for Phase 1 and 2 clinical trials. This collaboration is an important milestone in the ongoing partnership between the two companies, combining their strengths in science and manufacturing to ensure the timely and efficient development of Aramis’ vaccine.
Frédéric Ors, Co-founder and CEO of Aramis, expressed enthusiasm for the partnership, stating, “We are delighted to be working with Biodextris as a partner for downstream manufacturing and supply of clinical material.” He highlighted how this collaboration aligns with Aramis’ business strategy to leverage external expertise in preparing for potential future pandemic responses. He also praised Biodextris’ technical problem-solving and high-quality standards as key factors in making them the ideal partner for this critical production.
Cédric Héroux, General Manager of Biodextris, echoed the sentiment, emphasising how the partnership with Aramis resonated deeply with Biodextris’ mission to make impactful health solutions accessible globally. He expressed excitement about supporting the development of this innovative vaccine.
This partnership is a critical step in ensuring the rapid and efficient development of Aramis’ seasonal influenza vaccine, which could play a key role in enhancing protection for vulnerable populations worldwide. The collaboration also reflects the growing trend of leveraging contract manufacturing expertise to accelerate the development of life-saving treatments.